Recurrent Genomic Alterations in Pediatric and Adult Central Nervous System Tumors Detected by Chromosomal Microarray: Difference between revisions
No edit summary |
No edit summary |
||
| Line 69: | Line 69: | ||
'''Loss:''' CDKN2A/CDKN2B | '''Loss:''' CDKN2A/CDKN2B | ||
| CDKN2A/CDKN2B loss may correlate with anaplastic histology | | CDKN2A/CDKN2B loss may correlate with anaplastic histology | ||
| WHO CNS Tumors (2016) | | WHO CNS Tumors (2016)<br> | ||
PMID:25318587; PMID:23096133; PMID:21274720 | |||
|- | |- | ||
|Glioblastoma, WHO grade IV | |Glioblastoma, WHO grade IV | ||
| Line 96: | Line 97: | ||
|Overall poor prognosis regardless of subgroup | |Overall poor prognosis regardless of subgroup | ||
|PMCID:3280796; PMID:24705254; PMID:24705252 PMID:27048880; PMID:26175967; PMID:24705251; PMID:28966033 | |PMCID:3280796; PMID:24705254; PMID:24705252 PMID:27048880; PMID:26175967; PMID:24705251; PMID:28966033 | ||
|- | |||
|'''EPENDYMOMA'''<br> | |||
(in order of increasing WHO grade) | |||
| | |||
|'''DNA-based methylation classifies''' tumors across anatomical sites (posterior fossa, supratentorial, spinal), grades and age groups | |||
|'''Fusion:''' YAP1 fusions (supratentorial tumors)<br> | |||
'''Mutation:''' NF2 (spinal tumors)<br> | |||
'''Loss:''' CDKN2A | |||
|Intracranial (in children, 90%) or spinal tumors; Histological distinction between WHO grade II and III is of questionable relevance; Prognostic differences among tumors suggested on the basis of methylation analysis | |||
|WHO CNS Tumors (2016)<br> | |||
PMID:25965575; PMID:21627842; PMID:24939246; PMID:22516549 | |||
|- | |||